Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …

F Zappa, C Droege, D Betticher, R von Moos… - Lung cancer, 2012 - Elsevier
PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line
combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) …
被引用次数：39 相关文章

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …

F Zappa, C Droege, D Betticher, R von Moos… - Lung …, 2012 - lungcancerjournal.info
Purpose This phase II trial aimed to evaluate feasibility and efficacy of a first-line
combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) …

[引用][C] Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …

F Zappa, C Droege, D Betticher… - Lung …, 2012 - kalaidos-fh.elsevierpure.com
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell
lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease …

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …

F Zappa, C Droege, D Betticher, R von Moos… - Lung Cancer, 2012 - infona.pl
This phase II trial aimed to evaluate feasibility and efficacy of a first-line combination of
targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) and erlotinib (E) …
[PDF] academia.edu

[PDF][PDF] Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …

F Zappa, C Droege, D Betticher, R von Moos… - Lung …, 2012 - academia.edu
abstract Purpose: This phase II trial aimed to evaluate feasibility and efficacy of a first-line
combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) …

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …

F Zappa, C Droege, D Betticher, R von Moos… - Lung Cancer, 2012 - zora.uzh.ch
PURPOSE: This phase II trial aimed to evaluate feasibility and efficacy of a first-line
combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) …

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …

F Zappa, C Droege, D Betticher… - Lung Cancer …, 2012 - europepmc.org
Purpose This phase II trial aimed to evaluate feasibility and efficacy of a first-line
combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) …

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …

F Zappa, C Droege, D Betticher, R von Moos… - Lung cancer, 2012 - boris.unibe.ch
BORIS Deutsch English Français Login BORIS Bern Open Repository and Information System
University of Bern Home Statistics Bevacizumab and erlotinib (BE) first-line therapy in …

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …

F Zappa, C Droege, D Betticher… - Lung cancer …, 2012 - pubmed.ncbi.nlm.nih.gov
Purpose This phase II trial aimed to evaluate feasibility and efficacy of a first-line
combination of targeted therapies for advanced non-squamous NSCLC: bevacizumab (B) …

[引用][C] Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC)(stage IIIB/IV) followed by platinum-based …

F ZAPPA, C DROEGE, T HESS, D RAUCH… - Lung …, 2012 - pascal-francis.inist.fr
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung
cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease …